Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Amortization of Deferred Charges: 2013-2024

Historic Amortization of Deferred Charges for ImmunityBio (IBRX) over the last 6 years, with Dec 2024 value amounting to $22.6 million.

  • ImmunityBio's Amortization of Deferred Charges fell 29.66% to $5.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $22.6 million, marking a year-over-year decrease of 46.72%. This contributed to the annual value of $22.6 million for FY2024, which is 46.72% down from last year.
  • Per ImmunityBio's latest filing, its Amortization of Deferred Charges stood at $22.6 million for FY2024, which was down 46.72% from $42.4 million recorded in FY2023.
  • In the past 5 years, ImmunityBio's Amortization of Deferred Charges registered a high of $42.4 million during FY2023, and its lowest value of $12.4 million during FY2021.
  • In the last 3 years, ImmunityBio's Amortization of Deferred Charges had a median value of $22.6 million in 2024 and averaged $27.1 million.
  • In the last 5 years, ImmunityBio's Amortization of Deferred Charges spiked by 160.39% in 2023 and then tumbled by 46.72% in 2024.
  • Yearly analysis of 4 years shows ImmunityBio's Amortization of Deferred Charges stood at $12.4 million in 2021, then surged by 31.13% to $16.3 million in 2022, then spiked by 160.39% to $42.4 million in 2023, then slumped by 46.72% to $22.6 million in 2024.